Cellectar Biosciences to showcase strategic initiatives in developing cancer treatment drugs

From GlobeNewswire: 2025-01-12 18:00:00

Cellectar Biosciences presented data at ASH 2024 showing Iopofosine I 131 achieved an 83.6% ORR in Phase 2 CLOVER-WaM study for Waldenstrom’s Macroglobulinemia. Plans include advancing internally and with strategic partnerships for FDA and EMA approvals. The company is also advancing radiotherapeutic assets into Phase 1/2a Solid Tumor Studies. The CEO will present at the Biotech Showcase on January 14, 2025. Iopofosine is a cancer targeting agent with promising results, aiming for conditional market approval. The Company is focused on bringing lifesaving radioconjugates to patients and advancing clinical studies for other programs.

Cellectar Biosciences, a biopharmaceutical company, is developing cancer treatment drugs using a proprietary delivery platform. Lead assets include Iopofosine I 131 and CLR 121225 for solid tumors. The company’s pipeline also includes CLR 121125 for triple negative breast cancer. Iopofosine I 131 has received Orphan Drug and Fast Track Designations from the FDA. The company’s forward-looking statements highlight the risks and uncertainties involved in drug discovery and development. For more information, visit Cellectar’s website or social media channels.



Read more at GlobeNewswire: Cellectar Biosciences to Highlight 2025 Strategic